A detailed history of China Universal Asset Management Co., Ltd. transactions in Novavax Inc stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 26,878 shares of NVAX stock, worth $319,848. This represents 0.02% of its overall portfolio holdings.

Number of Shares
26,878
Previous 26,878 -0.0%
Holding current value
$319,848
Previous $128,000 -0.0%
% of portfolio
0.02%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$3.76 - $6.02 $49,387 - $79,072
13,135 Added 95.58%
26,878 $128,000
Q4 2023

May 21, 2024

SELL
$4.8 - $7.67 $63,048 - $100,745
-13,135 Reduced 48.87%
13,743 $65,000
Q4 2023

Jan 23, 2024

BUY
$4.8 - $7.67 $54,331 - $86,816
11,319 Added 466.96%
13,743 $66,000
Q3 2023

May 21, 2024

BUY
$6.81 - $9.74 $8,805 - $12,593
1,293 Added 114.32%
2,424 $17,000
Q3 2023

Oct 30, 2023

BUY
$6.81 - $9.74 $8,805 - $12,593
1,293 Added 114.32%
2,424 $18,000
Q2 2023

May 21, 2024

SELL
$6.67 - $9.52 $240 - $342
-36 Reduced 3.08%
1,131 $8,000
Q2 2023

Jul 27, 2023

SELL
$6.67 - $9.52 $240 - $342
-36 Reduced 3.08%
1,131 $8,000
Q1 2023

May 21, 2024

BUY
$5.76 - $12.48 $1,802 - $3,906
313 Added 36.65%
1,167 $8,000
Q1 2023

Apr 27, 2023

BUY
$5.76 - $12.48 $1,802 - $3,906
313 Added 36.65%
1,167 $8,000
Q4 2022

May 21, 2024

SELL
$8.86 - $25.04 $230,572 - $651,640
-26,024 Reduced 96.82%
854 $8,000
Q4 2022

Jan 31, 2023

BUY
$8.86 - $25.04 $575 - $1,627
65 Added 8.24%
854 $9,000
Q3 2022

Oct 21, 2022

BUY
$18.2 - $76.12 $13,340 - $55,795
733 Added 1308.93%
789 $14,000
Q4 2021

Feb 11, 2022

BUY
$134.56 - $217.97 $7,535 - $12,206
56 New
56 $8,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $931M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.